生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BK4139 生物科技

未开盘 04-07 16:00:00 EDT

1,106.02

-2.62

-0.24%

最高1,108.64	最低1,088.66	成交量14.85亿
今开1,108.63	昨收1,108.63	日振幅1.80%
总市值0.00	流通市值0.00	总股本0.00
成交额142.03亿	换手率--	流通股本0.00
市净率6.77937	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BK4139","market":"US","secType":"PLATE","nameCN":"生物科技","latestPrice":1106.0168,"timestamp":1775591999999,"preClose":1108.633,"halted":0,"volume":1484943018,"delay":0,"changeRate":-0.00236,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-2.616211,"latestTime":"04-07 16:00:00 EDT","open":1108.6305,"high":1108.641,"low":1088.662,"amount":14202815934.969582,"amplitude":0.018021,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775655000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":6.77937,"peRate":-208.990902,"increases":0,"decrements":0,"flats":0},"requestUrl":"/m/hq/s/BK4139","defaultTab":"news","newsList":[{"id":"1183859739","title":"Equillium Inc. 股东售股计划：包含可行使预融资权证发行的1770万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1183859739","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183859739?lang=zh_cn&edition=full","pubTime":"2026-04-08 05:17","pubTimestamp":1775596630,"startTime":"0","endTime":"0","summary":"Equillium Inc. 宣布其股东售股计划中，包含一项重要条款：通过行使预融资权证，可发行高达1770万股的公司普通股。这一安排为股票的潜在增发提供了明确路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EQ","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135444894","title":"Insmed研究未达主要及次要疗效终点 公司将终止HS项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1135444894","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135444894?lang=zh_cn&edition=full","pubTime":"2026-04-08 04:02","pubTimestamp":1775592132,"startTime":"0","endTime":"0","summary":"Insmed公司宣布，其最新研究未能达到预设的主要疗效终点和次要疗效终点指标。基于这一结果，公司决定终止HS项目的后续开发。\n该临床试验结果的公布，意味着Insmed在相关治疗领域的探索暂告一段落。公司表示将继续评估其他研发管线的进展，优化资源分配。\n此次研究数据的披露，为投资者和行业观察者提供了该公司研发进展的重要参考依据。市场将密切关注Insmed后续的战略调整和管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0053671581.USD","LU0320765992.SGD","LU0109394709.USD","INSM","LU0889565916.HKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130614255","title":"吉利德科学再度出手收购癌症药物合作伙伴——市场快讯","url":"https://stock-news.laohu8.com/highlight/detail?id=1130614255","media":"投资观察","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130614255?lang=zh_cn&edition=full","pubTime":"2026-04-07 22:26","pubTimestamp":1775572014,"startTime":"0","endTime":"0","summary":"吉利德科学公司再度出手收购其癌症药物合作伙伴，该公司已达成协议，将以最高50亿美元的价格收购Tubulis公司。今年二月，吉利德宣布将收购ARCELLX, INC.的全部剩余股份，该公司是吉利德在开发针对多发性骨髓瘤这一血癌的潜在CAR-T细胞疗法方面的合作伙伴，该交易对这家生物技术公司的估值在交易完成时约为78亿美元。\nRBC资本市场的分析师指出，此次收购Tubulis是一项战略上合理的补充性收购，既能满足吉利德肿瘤学产品管线增长的需求，又能确保获得差异化的下一代抗体偶联药物平台能力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0122379950.USD","LU0882574055.USD","LU2087621335.USD","LU0109394709.USD","LU0965509283.SGD","LU0965508806.USD","LU2089984988.USD","LU2468319806.SGD","BK4568","LU0823416689.USD","BK4585","LU1057294990.SGD","LU1061106388.HKD","BK4550","LU1839511570.USD","LU0114720955.EUR","SG9999015986.USD","LU1037948897.HKD","LU1674673428.USD","LU0861579265.USD","IE00BKVL7J92.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","IE00B7SZLL34.SGD","IE0002270589.USD","LU1674673691.USD","LU1066053197.SGD","LU1934455194.USD","LU1571399168.USD","LU2324357040.USD","LU0320765992.SGD","BK4583","BK4566","LU1430594728.SGD","SG9999015978.USD","IE00BZ1G4Q59.USD","SG9999015952.SGD","LU1066051498.USD","BK4532","LU0058720904.USD","IE00B3T34201.USD","LU0965509101.SGD","LU1934455277.USD","BK4578","LU2112291526.USD","BK4139","LU1934455863.HKD","GILD","LU1023059063.AUD","SG9999015945.SGD","LU1778281490.HKD","LU0289739699.SGD","LU0965509010.AUD","IE00B19Z3581.USD","LU0234570918.USD","LU1037948541.HKD","LU1585245621.USD","BK4588","ACLX","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625303955","title":"50亿美元掷向ADC赛道，吉利德科学(GILD.US)高价收购德国Tubulis","url":"https://stock-news.laohu8.com/highlight/detail?id=2625303955","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625303955?lang=zh_cn&edition=full","pubTime":"2026-04-07 21:15","pubTimestamp":1775567710,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，吉利德科学同意收购德国私营生物技术公司 Tubulis GmbH，交易总价值高达 50 亿美元。吉利德目前已经销售一种名为 Trodelvy 的乳腺癌 ADC 药物。Tubulis 正在针对卵巢癌、肺癌以及其他类型的肿瘤进行药物临床试验。数据显示，卵巢癌市场到 2030 年的价值可能达到 56 亿美元，Tubulis 在该领域有潜力挑战阿斯利和礼来等巨头。这是吉利德今年以来的第三笔重大交易。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425591.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0965508806.USD","LU0823416689.USD","LU2112291526.USD","GILD","LU0965509101.SGD","IE00B3T34201.USD","LU2089984988.USD","LU1585245621.USD","LU1934455194.USD","SG9999015986.USD","LU0965509010.AUD","ADC","LU0889565916.HKD","LU1037948541.HKD","IE00BZ1G4Q59.USD","BK4532","LU0320765992.SGD","FDAXmain","IE00BSNM7G36.USD","LU1057294990.SGD","FDXSmain","LU0234570918.USD","LU0861579265.USD","BK4550","LU1023059063.AUD","LU1934455277.USD","LU2468319806.SGD","BK4566","LU0122379950.USD","BK4583","LU1061106388.HKD","SG9999015978.USD","BK4568","LU2324357040.USD","BK4231","LU0882574055.USD","IE00B19Z3B42.SGD","BK4578","BK4588","IE00BKVL7J92.USD","LU0965509283.SGD","LU1066053197.SGD","FDXMmain","IE0002270589.USD","LU0289739699.SGD","LU1674673691.USD","LU0114720955.EUR","BK4139","LU1839511570.USD","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155608590","title":"阿卡迪亚制药宣布Daybue® Stix（曲非奈肽）现已在美国全面上市，用于治疗雷特综合征","url":"https://stock-news.laohu8.com/highlight/detail?id=1155608590","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155608590?lang=zh_cn&edition=full","pubTime":"2026-04-07 21:05","pubTimestamp":1775567111,"startTime":"0","endTime":"0","summary":"阿卡迪亚制药（ACADIA Pharmaceuticals）正式宣布，其用于治疗雷特综合征的药物Daybue® Stix（曲非奈肽）目前在美国市场已实现广泛供应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171311.SGD","LU2065171402.SGD","LU2065169927.USD","LU2065170008.USD","BK4139","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164642417","title":"Outlook Therapeutics宣布FDA已受理关于Ons-5010/Lytenava™（贝伐珠单抗-Vikg）的正式争议解决申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1164642417","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164642417?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:50","pubTimestamp":1775566215,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics, Inc.披露，美国食品药品监督管理局（FDA）已正式接受该公司针对其核心候选药物Ons-5010/Lytenava™（贝伐珠单抗-Vikg）所提交的正式争议解决请求。这一进展标志着公司在推动该眼科疗法获批的进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109962795","title":"吉利德科学将收购Tubulis，引入潜在同类最佳抗体偶联药物及新一代平台，进一步强化肿瘤产品管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1109962795","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109962795?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:31","pubTimestamp":1775565084,"startTime":"0","endTime":"0","summary":"吉利德科学宣布收购Tubulis公司，此举将为公司带来潜在同类最优的抗体偶联药物以及新一代技术平台，从而显著增强其在肿瘤治疗领域的产品管线布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00B7SZLL34.SGD","IE00BKVL7J92.USD","SG9999015952.SGD","LU0965509283.SGD","LU0289739699.SGD","LU2089984988.USD","LU1430594728.SGD","IE00BSNM7G36.USD","LU1037948897.HKD","LU1037948541.HKD","LU0109394709.USD","LU1066053197.SGD","BK4568","LU1934455863.HKD","LU1023059063.AUD","LU2324357040.USD","BK4583","IE00BZ1G4Q59.USD","LU1571399168.USD","LU0320765992.SGD","IE00B19Z3581.USD","LU1061106388.HKD","LU1778281490.HKD","IE0002270589.USD","LU0882574055.USD","IE00B19Z3B42.SGD","LU1839511570.USD","LU1585245621.USD","GILD","BK4566","LU2468319806.SGD","LU1674673428.USD","LU2112291526.USD","SG9999015978.USD","LU0861579265.USD","LU0234570918.USD","SG9999015945.SGD","BK4550","LU1674673691.USD","BK4532","BK4585","IE00B3T34201.USD","LU0965508806.USD","LU1934455194.USD","LU0122379950.USD","LU0114720955.EUR","LU0058720904.USD","LU1934455277.USD","LU0823416689.USD","LU1066051498.USD","LU0889565916.HKD","LU1057294990.SGD","BK4578","LU0965509010.AUD","LU0965509101.SGD","LU2087621335.USD","SG9999015986.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156303425","title":"Piper Sandler将Soleno Therapeutics评级从增持下调至中性，目标价从145美元大幅削减至53美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1156303425","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156303425?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:25","pubTimestamp":1775564715,"startTime":"0","endTime":"0","summary":"Piper Sandler宣布，将生物制药公司Soleno Therapeutics的股票评级从\"增持\"下调至\"中性\"。同时，该机构将其目标股价从145美元大幅下调至53美元，显示出对公司短期前景的谨慎态度。此次评级和目标价的双重调整，可能影响市场对该股的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLNO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176735830","title":"Savara宣布英国MHRA受理Molgradex治疗自身免疫性肺泡蛋白沉积症的上市许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1176735830","media":"投资观察","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176735830?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:21","pubTimestamp":1775564504,"startTime":"0","endTime":"0","summary":"Savara Inc宣布，英国药品和保健品管理局（MHRA）已正式受理其药物Molgradex用于治疗自身免疫性肺泡蛋白沉积症的上市许可申请。\n根据公司披露的时间表，MHRA对Molgradex上市许可申请的决定预计将在2026年第四季度公布。与此同时，美国食品药品监督管理局（FDA）针对Molgradex生物制品许可申请设定的处方药用户付费法案目标日期为2026年8月22日。此外，欧洲药品管理局人用药品委员会对Molgradex上市许可申请的决定预计将于2027年第一季度作出。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111294591","title":"吉利德科学将以31.5亿美元现金预付款收购Tubulis，潜在里程碑金额高达18.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111294591","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111294591?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:19","pubTimestamp":1775564350,"startTime":"0","endTime":"0","summary":"生物制药巨头吉利德科学宣布达成一项重大收购协议，将以31.5亿美元现金作为预付款，收购专注于抗体偶联药物研发的德国生物技术公司Tubulis。根据协议条款，若Tubulis在后续研发中达成特定里程碑，吉利德还将额外支付最高18.5亿美元的资金。此次交易凸显了吉利德科学在肿瘤治疗领域的战略布局。协议设计的里程碑付款机制，既体现了吉利德对Tubulis技术潜力的认可，也显示出其对研发成果的审慎评估。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4583","GILD","LU1066053197.SGD","LU1585245621.USD","LU0289739699.SGD","IE00B7SZLL34.SGD","IE00B3T34201.USD","IE00B19Z3581.USD","BK4578","BK4550","LU1934455194.USD","LU2324357040.USD","LU0320765992.SGD","LU0058720904.USD","SG9999015945.SGD","SG9999015986.USD","LU1023059063.AUD","LU1839511570.USD","LU0965508806.USD","LU1674673428.USD","LU0234570918.USD","LU1037948541.HKD","BK4139","LU0109394709.USD","LU0889565916.HKD","LU2112291526.USD","BK4568","BK4588","LU1934455863.HKD","LU0861579265.USD","LU1778281490.HKD","IE0002270589.USD","LU1430594728.SGD","LU0122379950.USD","LU2087621335.USD","LU1934455277.USD","SG9999015952.SGD","LU0114720955.EUR","LU1061106388.HKD","BK4566","LU1037948897.HKD","LU1571399168.USD","IE00BZ1G4Q59.USD","LU1057294990.SGD","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU0965509010.AUD","LU2089984988.USD","LU0965509283.SGD","IE00BSNM7G36.USD","LU2468319806.SGD","LU0965509101.SGD","LU1066051498.USD","LU0882574055.USD","LU1674673691.USD","BK4532","LU0823416689.USD","BK4585","SG9999015978.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115530780","title":"BioRestorative Therapies宣布与203 Creates达成战略合作，共同构建并商业化生物化妆品平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1115530780","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115530780?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:18","pubTimestamp":1775564322,"startTime":"0","endTime":"0","summary":"BioRestorative Therapies, Inc. 已正式宣布与203 Creates建立战略合作伙伴关系。双方将携手共建并推动其生物化妆品平台的商业化进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BRTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136489047","title":"吉利德科学将以31.5亿美元现金收购Tubulis全部流通股权，交易基于无现金无债务基础","url":"https://stock-news.laohu8.com/highlight/detail?id=1136489047","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136489047?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:18","pubTimestamp":1775564314,"startTime":"0","endTime":"0","summary":"吉利德科学宣布，将以31.5亿美元的前期现金对价，收购生物技术公司Tubulis的全部流通股权。此次交易将基于无现金、无债务的基础进行，标志着吉利德在拓展肿瘤治疗管线方面的重大战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015952.SGD","BK4568","LU2089984988.USD","LU1066053197.SGD","BK4583","LU1023059063.AUD","IE00B19Z3B42.SGD","LU0109394709.USD","LU0058720904.USD","BK4139","BK4532","LU1778281490.HKD","LU0965509283.SGD","SG9999015986.USD","LU0965509010.AUD","LU2468319806.SGD","LU1674673691.USD","LU1066051498.USD","BK4588","LU0289739699.SGD","IE00BSNM7G36.USD","LU1934455277.USD","IE0002270589.USD","LU1585245621.USD","LU1674673428.USD","LU1934455194.USD","LU2087621335.USD","BK4578","LU0122379950.USD","LU0234570918.USD","LU1430594728.SGD","BK4550","LU0965509101.SGD","IE00B7SZLL34.SGD","LU0889565916.HKD","LU2112291526.USD","LU1061106388.HKD","LU0823416689.USD","LU0965508806.USD","SG9999015978.USD","IE00BKVL7J92.USD","LU1037948897.HKD","IE00B3T34201.USD","LU1057294990.SGD","GILD","LU0114720955.EUR","LU0882574055.USD","LU1839511570.USD","BK4566","LU0320765992.SGD","LU1037948541.HKD","LU2324357040.USD","SG9999015945.SGD","BK4585","LU0861579265.USD","LU1571399168.USD","LU1934455863.HKD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118128124","title":"Cue Biopharma达成临床前里程碑，预计2026年5月获750万美元付款——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1118128124","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118128124?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:09","pubTimestamp":1775563760,"startTime":"0","endTime":"0","summary":"根据美国证券交易委员会最新文件披露，Cue Biopharma, Inc.因达成一项临床前研发里程碑，预计将于2026年5月获得750万美元的付款。这一里程碑的触发，标志着公司在特定药物研发项目上取得关键进展。该笔付款源于Cue Biopharma与合作伙伴达成的协议条款，临床前阶段的成功为后续开发奠定了坚实基础。对于专注免疫疗法开发的Cue Biopharma而言，此次资金注入将支持其持续推进创新生物制剂的研发管线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CUE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199822860","title":"Savara宣布英国药品和保健品管理局接受Molgradex上市许可申请用于治疗自身免疫性肺泡蛋白沉积症","url":"https://stock-news.laohu8.com/highlight/detail?id=1199822860","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199822860?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:06","pubTimestamp":1775563586,"startTime":"0","endTime":"0","summary":"Savara Inc. 宣布，英国药品和保健品管理局（MHRA）已正式受理其药物Molgradex®用于治疗自身免疫性肺泡蛋白沉积症（autoimmune PAP）的上市许可申请（MAA）。这一进展标志着该药物在英国监管审批流程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVRA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152892938","title":"Alzamend Neuro公布AL001“脑内锂”研究II期临床试验积极药效学数据，试验于麻省总医院进行","url":"https://stock-news.laohu8.com/highlight/detail?id=1152892938","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152892938?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:02","pubTimestamp":1775563336,"startTime":"0","endTime":"0","summary":"Alzamend Neuro公司宣布，其候选药物AL001（即“脑内锂”研究）在位于马萨诸塞州总医院进行的II期临床试验中，获得了令人鼓舞的药效学数据。这些积极结果标志着公司在开发新型锂疗法用于治疗神经精神疾病方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","ALZN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162623204","title":"Polyrizon Ltd. 签署协议进行普通股及预融资认股权证的注册直接发行","url":"https://stock-news.laohu8.com/highlight/detail?id=1162623204","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162623204?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:02","pubTimestamp":1775563325,"startTime":"0","endTime":"0","summary":"生物技术公司Polyrizon Ltd. (PLRZ) 近日宣布，该公司已达成最终协议，将通过注册直接发行的方式，向机构投资者发售其普通股及预融资认股权证。\n此次发行旨在为公司的重要研发项目及一般营运资金需求筹集资金。根据市场惯例，此次发行的完成仍需满足特定的交割条件。\n通过这种融资方式，Polyrizon Ltd. 期望能加速其在研管线的进展，并进一步巩固其财务状况。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLRZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154125617","title":"奥洛兹美医疗与福泰制药就Hypercon™技术达成全球合作与授权协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1154125617","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154125617?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563282,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗（Halozyme Therapeutics）宣布，已与福泰制药（Vertex Pharmaceuticals）就其专有的Hypercon™技术达成一项全球性的合作与许可协议。此项合作旨在利用Hypercon技术平台，共同探索和开发新的治疗方案。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","HALO","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160164211","title":"奥洛兹美医疗与Vertex达成协议，授权其Hypercon技术用于最多三个药物靶点","url":"https://stock-news.laohu8.com/highlight/detail?id=1160164211","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160164211?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563282,"startTime":"0","endTime":"0","summary":"奥洛兹美医疗（Halozyme Therapeutics）宣布，已与Vertex Pharmaceuticals就前者专有的Hypercon药物递送技术达成一项授权协议。根据协议条款，Vertex公司获得授权，可将此项技术应用于多达三个药物靶点的开发。\n这项合作凸显了Hypercon技术在提升治疗性药物效能方面的潜力。通过此项授权，Vertex旨在利用该技术平台优化其研发管线中特定候选药物的递送效率。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0053671581.USD","HALO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134165905","title":"Corbus Pharmaceuticals Holdings Inc 将继续与FDA沟通以敲定注册研究方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1134165905","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134165905?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563280,"startTime":"0","endTime":"0","summary":"Corbus Pharmaceuticals Holdings Inc (CRBP) 宣布，公司计划持续推进与美国食品药品监督管理局（FDA）的互动，旨在最终确定其关键注册研究的试验方案。这一步骤对于公司后续的新药申报及商业化进程至关重要。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRBP","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167034621","title":"Inhibikase Therapeutics启动首例患者入组，开展Ikt-001治疗肺动脉高压的全球三期IMPROVE-PAH研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1167034621","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167034621?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:01","pubTimestamp":1775563277,"startTime":"0","endTime":"0","summary":"Inhibikase Therapeutics, Inc. (简称Inhibikase) 宣布，其针对肺动脉高压（PAH）的创新疗法Ikt-001，已在全球三期临床试验IMPROVE-PAH中完成首例患者入组。这一重要进展标志着该药物临床开发进入关键阶段，有望为肺动脉高压患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":-0.0196},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0178},{"period":"1year","weight":0.307},{"period":"ytd","weight":-0.0333}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"name":"生物科技","nameEN":"BK4139"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"生物科技,BK4139,生物科技股票,生物科技股票老虎,生物科技股票老虎国际,生物科技行情,生物科技股票行情,生物科技股价,生物科技股市,生物科技股票价格,生物科技股票交易,生物科技股票购买,生物科技股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"生物科技(BK4139)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供生物科技(BK4139)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}